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The ubiquitin proteasome system (UPS) is crucial for intracellular protein homeostasis
and for degradation of aberrant and damaged proteins. The accumulation of ubiquitinated
proteins is a hallmark of many neurodegenerative diseases, including amyotrophic lateral
sclerosis, Alzheimer’s, Parkinson’s, andHuntington’s disease, leading to the hypothesis that
proteasomal impairment is contributing to these diseases. So far, most research related
to the UPS in neurodegenerative diseases has been focused on neurons, while glial cells
have been largely disregarded in this respect. However, glial cells are essential for proper
neuronal function and adopt a reactive phenotype in neurodegenerative diseases, thereby
contributing to an inﬂammatory response. This process is called reactive gliosis, which
in turn affects UPS function in glial cells. In many neurodegenerative diseases, mostly
neurons show accumulation and aggregation of ubiquitinated proteins, suggesting that
glial cells may be better equipped to maintain proper protein homeostasis. During an
inﬂammatory reaction, the immunoproteasome is induced in glia, which may contribute
to a more efﬁcient degradation of disease-related proteins. Here we review the role
of the UPS in glial cells in various neurodegenerative diseases, and we discuss how
studying glial cell function might provide essential information in unraveling mechanisms
of neurodegenerative diseases.
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THE UBIQUITIN PROTEASOME SYSTEM
Protein homeostasis is essential for proper function of a cell;
therefore both protein synthesis and degradation are tightly reg-
ulated. Although there is a complex interplay between the two
systems, in general, there are two main machineries involved
in protein degradation: autophagy and the ubiquitin protea-
some system (UPS). Autophagy involves lysosomal degradation
by the formation of intracellular vesicles (autophagosomes) and is
subdivided in chaperone-mediated autophagy (CMA), microau-
tophagy, and macroautophagy. In CMA, chaperone proteins
bind speciﬁcally to a KFERQ domain in a cytosolic protein,
afterward it is internalized and degraded. Microautophagy is
the direct lysosomal digestion of cytoplasmic content, which is
trapped by random invagination of the lysosomal membrane.
Macroautophagy functions as bulk degradation of mainly long-
lived proteins, protein aggregates and organelles, and involves
autophagosome formation to isolate cytoplasmic proteins. The
UPS selectively targets individual proteins, including short-lived,
damaged or defectively folded proteins, which accounts for
about 80–90% of all intracellular proteins (Rock et al., 1994;
Lilienbaum, 2013).
The UPS consists of two key components: the ubiquitination
system, which selects and targets proteins towards degradation
by ubiquitinating them, and the proteasome, a multimeric pro-
tein complex that actually performs the degradation. Protein
degradation is a tightly regulated process: before a protein is
cleaved by the proteasome, an elaborate process of selection and
targeting has taken place exerted by the ubiquitin (Ub) system.
This system mediates the conjugation of Ub, a small 76-amino-
acid-long modiﬁer. Binding of Ub to the target protein takes place
in a three-step reaction. First, Ub is linked to an Ub-activating
enzyme (E1) in an ATP-dependent manner. Subsequently, the
activated Ub is transferred to an E2 conjugating enzyme, fol-
lowed by attachment of E2 to a speciﬁc E3 ubiquitin ligase
enzyme that binds the target protein. Lastly, Ub is transferred
by the E2 enzyme to the target protein (Figure 1). Ub itself
can be ubiquitinated at one of its seven lysine residues, result-
ing in various polyubiquitin chain types that each has its own
speciﬁc signal function. Regulation of protein degradation is also
mediated by deubiquitinating enzymes (DUBs) that can reverse
ubiquitination by removing Ub residues of mono- or polyubiq-
uitinated proteins (Glickman and Ciechanover, 2002; Lilienbaum,
2013).
Polyubiquitinated proteins are generally degraded by the 26S
proteasome, which consists of a barrel-shaped 20S core that is
the actual protease and a 19S regulatory complex that recog-
nizes and unfolds the ubiquitinated substrate (Figure 1). The
20S core consists of two rings of seven α subunits, ﬂanking
two rings of seven β subunits. Three of these seven β sub-
units are catalytically active, with a caspase-like (β1), trypsin-like
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FIGURE 1 | Scheme of the ubiquitin proteasome system. Proteins are
targeted for degradation by ubiquitination via E1, E2, and E3 enzymes. The
proteasome recognizes and removes the ubiquitination signal, unfolds the
protein and ﬁnally degrades it.
(β2), or chymotrypsin-like (β5) activity that cleave after nega-
tively charged, positively charged, and hydrophobic amino acids,
respectively (Lilienbaum, 2013). The 19S regulatory complex rec-
ognizes and unfolds the ubiquitinated substrate and guides it
into the 20S core. The 19S complex consists of 19 individual
proteins, of which six are ATPases of the AAA family (Baumeis-
ter et al., 1998). Binding of ATP is necessary for assembly of
the 20S core with the 19S cap, subsequently ATP hydrolysis is
required for protein unfolding, while for the next steps, gate open-
ing, translocation and degradation, only ATP binding is required
(Smith et al., 2005).
Next to the 19S complex, also other regulatory protea-
some activators (PA) exist, including 11S (PA28), PI31, and
PA200, which bind the 20S core in an ATP-independent way
(Lilienbaum, 2013). PA28αβ expression is induced upon secre-
tion of interferon gamma (IFNγ) and plays a role in processing
peptides for MHC class I antigen presentation (Realini et al.,
1994; Sijts and Kloetzel, 2011). When PA28αβ binds to 20S core,
the activities of all β-subunits are increased, which is probably
due to an increased accessibility rather than alterations within
the active sites themselves. In contrast to PA28αβ, the exact
mechanism that PA28γ, which is only expressed in the nucleus,
uses to exert its function is not known (Rechsteiner and Hill,
2005).
IFNγ not only induces different PA caps but also induces
the expression and incorporation of the proteasomal immuno-
subunits β1i (LMP2), β2i (Mecl-1), and β5i (LMP7) that sub-
stitute β1, β2, and β5, respectively. With this replacement, the
chymotrypsin-like activity increases and the immunoproteasome
shows an altered cleavage pattern, resulting in different peptides
being generated that are subsequently presented by MHC class-I
molecules to the cells of the immune system (Sijts and Kloetzel,
2011; Basler et al., 2013).
GLIAL CELLS
Neuroglia were ﬁrst described by the German pathologist Rudolf
Virchow already more than 150 years ago. For a long time these
cells were considered as nerve glue, a kind of connective tissue
holding the brain together. In contrast to neurons, glia are not
electrically excitable. This made it difﬁcult to study these cells, and
as a consequence, most neuroscientiﬁc research was focused on
neuronal function. When sophisticated molecular tools became
available which made it possible to study the physiology of glial
cells, this has led to a change in the neurocentric view of neu-
roscientists. During the last decades, it has become evident that
glial cells are essential for proper neuronal function, are actively
involved in neuronal communication, and form the immune
system of the brain. As diverse as different glial cells are in mor-
phology and origin, as diverse they are likely in their function.
They take care of the general homeostasis in the brain, insulate
neurons, and protect against pathogenic invaders (Kettenmann
and Verkhratsky, 2008). The ratio between neurons and glia in
the human central nervous system (CNS) is about 1:1, with oligo-
dendrocytes being the most abundant type of glial cells (75.6%),
followed by astrocytes (17.3%) and microglia (6.5%) in human
male brains (Pelvig et al., 2008). Below, the most important glial
cell types and their functions are described (Figure 2).
ASTROCYTES
Astrocytes perform a variety of crucial tasks in the CNS. Similar to
neurons, astrocytes are of ectodermal origin. During theﬁrst stages
of embryogenesis, the ﬁrst astrocyte precursor cells arise fromneu-
ral stem cells. These radial glia function as neural progenitors and
form the scaffold that is used by immature neurons to migrate
toward their ﬁnal location. In a later stage, these cells give rise to the
progenitors of oligodendrocytes as well as to the different kinds of
astrocytes in the brain. The astrocyte population is broad and het-
erogeneous and the classiﬁcation of subtypes is in its initial stage.
Astrocytes contact multiple blood vessels with their endfeet, and
they connect to neighboring astrocytes via gap junctions. Besides,
astrocytes envelope multiple synapses and ﬁbrous astrocytes in the
white matter contact several nodes of Ranvier, which are the small
gaps in myelinated axons (Sofroniew and Vinters, 2010; Molof-
sky et al., 2012). Subventricular astrocyte-like cells are the stem
cells in the brain. The progeny of these cells migrate through the
rostral migratory stream into the olfactory bulb, and differentiate
into interneurons. When isolated and brought in culture, they can
differentiate in both neurons and glia thus exhibiting multipotent
properties (Mamber et al., 2013). These cells are even still present
in aged brains, suggesting regenerative potential until late in life
(Van Den Berge et al., 2010).
In the mature brain, astrocytes inﬂuence synaptic trans-
mission directly by the release of gliotransmitters including
glutamate, ATP, GABA, and D-serine, although it is not fully
understood how the cells release these transmitters. Astrocytes
also respond to neurotransmitters, which leads to a surge in
Frontiers in Molecular Neuroscience www.frontiersin.org August 2014 | Volume 7 | Article 73 | 2
Jansen et al. UPS in glia during neurodegeneration
FIGURE 2 |The role of various glial cells in the healthy and diseased CNS.
(A) In the healthy situation, astrocytes support neurons by ﬁltering nutrients
from the blood and modulating synapses, oligodendrocytes wrap axons in
isolating myelin sheets and microglia scan the environment for dead cells or
invading pathogens. (B) During reactive gliosis in neurodegenerative
diseases, oligodendrocytes and astrocytes lose their normal support function.
Astrocytes decrease glutamate uptake from the synapse, leading to
excitotoxicity. Microglia become activated and phagocytize dead cells and
start to secrete pro-inﬂammatory cytokines that activate astrocytes. Both
reactive astrocytes and activated microglia upregulate immunoproteasome
expression. In particular diseases, demyelination of the axons is observed
due to oligodendrocyte dysfunction.
calcium. Although astrocytes do have voltage-gated channels
(Pappalardo et al., 2014), they are not able to respond with an
increase in calcium in a millisecond time scale. Hence, astro-
cytes play a modulatory role: they are likely to inﬂuence synaptic
communication of the many neurons in their domain. Astrocytes
can also regulate synaptic transmission by mediating homeosta-
sis of ions, pH and (neuro)transmitters. A well-known function
of astrocytes is uptake of glutamate from the synaptic cleft via
glutamate transporter Glt-1. Moreover, astrocytes contain trans-
porters for the neurotransmitters GABA and glycine, for K+
ions, bicarbonate, water and monocarboxylic acid (Sofroniew
and Vinters, 2010). Recently, it has been shown that astrocytes
are able to inﬂuence synapses also by synaptic pruning both
in the developing and in the adult mouse brain. This phago-
cytosis of synapses is dependent on neuronal activity and is
mediated via the Mertk and Megf10 pathways. Thus, astro-
cytes actively contribute to activity-dependent synapse elimi-
nation and CNS remodeling (Chung et al., 2013). Next to the
phagocytosis of synapses, activated astrocytes are able to phago-
cytize amyloid β deposits in vitro and in situ (Wyss-Coray et al.,
2003).
Furthermore, astrocytes form a key compartment of the blood
brain barrier (BBB); they are not only involved in induction
and development of the BBB, they also regulate BBB perme-
ability (Abbott, 2002). Astrocytes are connecting the blood
vessels with many neuronal perikarya, axons and synapses.
Therefore, astrocytes are the ideal cells to make an important
contribution to the energy supply of the brain; for exam-
ple by taking up glucose from the blood via their glucose
transporters.
In conclusion, astrocytes are a heterogeneous group of glial
cells that exert numerous tasks essential for proper neuronal
function. They are indispensable in neurodevelopment, synap-
tic communication and brain homeostasis. As a consequence,
loss or change in astrocyte function can contribute to patho-
genesis of neurodegenerative diseases. A clear example is
the leukodystrophy Alexander’s disease, which is caused by
a mutation in the astrocyte speciﬁc gene GFAP that leads
to astrocyte pathology and dysfunction (Brenner et al., 2001;
Sosunov et al., 2013).
OLIGODENDROCYTES
Oligodendrocytes are the myelinating cells of the brain, and
form an insulating myelin sheath around the axonal segments
of neurons. Like astrocytes, oligodendrocytes are of ectodermal
origin; they arise from the neural stem cells in the neuroep-
ithelium during early embryogenesis. The onset of myelination,
as well as the selection of axons that require myelination, are
both tightly regulated. Neuronal activity and degree of differen-
tiation, together with several surface receptors (e.g., LINGO-1),
inﬂuence the brain area and speciﬁc axons that are myelinated
(Baumann and Pham-Dinh, 2001; Bradl and Lassmann, 2010).
As oligodendrocytes have only a short time window wherein they
are capable of myelination, this provides temporal control during
early differentiation as well (Baumann and Pham-Dinh, 2001). A
single oligodendrocyte can enwrap multiple axons, while a sin-
gle axon can have adjacent myelin sheets belonging to different
oligodendrocytes. Myelination of axons is important for a high-
speed, reliable conduction of electrical signals between neurons.
The myelinated ﬁbers contain small gaps named nodes of Ran-
vier that are important for the fast signal conduction, so the
action potential can jump from node to node. During the peak
of myelination, about three times the weight of the oligodendro-
cyte is produced in myelin each day. Small changes in protein
homeostasis will therefore have huge consequences for protein
production and quality control, which can result in misfolding
and accumulation of proteins and cause dysfunctional oligoden-
drocytes and eventually demyelination. Illustratively, transgenic
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rat overexpressing the oligodendrocyte proteolipid protein showed
oligodendrocyte apoptosis and dysmyelination (Baumann and
Pham-Dinh, 2001; Bradl and Lassmann, 2010). Axons can be
remyelinated by new oligodendrocytes arising from the NG2+
cells that are stimulated to divide and differentiate by activated
microglia and astrocytes. However, the resulting myelin sheath
is thinner, possibly due to the lack of stimulating growth factors
that were initially secreted by the growing axon. Oligodendro-
cyte dysfunction is directly detrimental for neuronal function
and leads to neurodegeneration in the α-synucleinopathy multi-
ple system atrophy (MSA), but also in multiple sclerosis and other
leukodystrophies (Baumann and Pham-Dinh, 2001; Kuzdas et al.,
2013).
MICROGLIA
Microglia primarily function as the immune cells of the
CNS. In contrast to astrocytes and oligodendrocytes, microglia
are from mesodermal origin (Ginhoux et al., 2010) and are
derived from hematopoietic stem cells in the yolk sac early
in embryonic development (Alliot et al., 1999). Although
microglia are mostly known for their function in the immune
response under disease conditions, they also play an impor-
tant role in CNS homeostasis. During neuronal development,
microglia regulate brain plasticity, by controlling synapses
(Kettenmann et al., 2013). Next to phagocytizing apoptotic cells
and pruning synapses during development, microglia are
actively involved in promoting apoptosis, which is also an
important aspect of neuronal development (Kettenmann et al.,
2013). In the adult brain, microglia also phagocytize dead
neurons and express several receptors for neurotransmitters,
-peptides, and -modulators, thereby sensing (changes in) neu-
ronal activity. Under healthy conditions, microglia have a
small nucleus and long, thin, very motile processes, and
although called “resting microglia,” these cells are constantly
monitoring the environment and when dying neurons are
detected, microglia become activated. Subsequent phagocyto-
sis is a tightly regulated process involving multiple receptors
like CD36, lectin, and integrin receptors (Kettenmann et al.,
2013).
Next to neuronal damage, invading pathogens are detected
and cleaned up by microglia (Aloisi, 2001). To recognize
and eliminate foreign entities, a variety of pattern recog-
nition receptors are expressed including complement recep-
tor 3 and toll-like receptors (TLR) 2, 4, and 9 that
promote phagocytosis and recognize bacterial lipopolysaccha-
ride (LPS; TLR2, 4) or DNA (TLR9). These cytokines are
secreted by CNS associated macrophages, astrocytes and by
other microglia as a paracrine activation mechanism. TNF-
α, IL-1, and IFNγ are pro-inﬂammatory cytokines that acti-
vate the immune functions of microglia including phago-
cytosis, cytokine production and antigen presentation. The
immune response is regulated by anti-inﬂammatory cytokines
such as IL-10, TGF-β, which downregulate the expres-
sion of proinﬂammatory cytokines, reactive oxygen species
(ROS), chemokines and other molecules associated with
phagocytosis in microglia (Aloisi, 2001; Tambuyzer et al.,
2009).
GLIA IN PATHOLOGY
Early pathological studies showed astrogliosis and microglial
proliferation in damaged brain tissues in several neurodegen-
erative diseases including Huntington’s disease (HD; Faideau
et al., 2010), Alzheimer’s disease (AD; Sheng et al., 1997; Mrak,
2009), but also in inﬂammatory diseases, brain trauma, ischemia
and infection (Gray et al., 1996; Tambuyzer et al., 2009; Amor
et al., 2013; Pekny et al., 2014). Since microglia sense neuronal
damage, they might be the initiators of the glial reaction to
neuronal pathology, which is called neuroinﬂammation (reac-
tive gliosis). Activated microglia have been shown to secrete
cytokines that induce astrocyte reactivity. This is a delayed
reaction; microglia are sensitive for the smallest pathological
changes in the CNS, but only when the damage is severe enough
this will lead to astrogliosis. Astrogliosis is characterized by
increased expression of the astrocyte-speciﬁc intermediate ﬁla-
ment GFAP (Pekny et al., 2014) and vimentin (Parpura et al.,
2012). Astrocytes express cytokine receptors for, e.g., IL-1, IL-
6, and TNF-α, and microglia might disturb normal astrocyte
function by activating astrocytes via these receptors. For exam-
ple, TNF-α affects glutamate transmission directly by inhibiting
expression of astrocytic glutamate transporters (Cumiskey et al.,
2005). As a result of activation, astrocytes release cytokines
that can in turn inﬂuence microglial function (Amor et al.,
2013). Hereby a feedback loop is created, in which fac-
tors from both astrocytes and microglia regulate each other
(Zhang et al., 2010).
It is unclear whether glial activation under pathological cir-
cumstances is beneﬁcial or detrimental. Activation of astrocytes is
initially meant to protect neurons by forming a protective border
around the damaged site (Pekny et al., 2014), but loss-of-function
of astrocytes such as reduced glutamate uptake may also result
in neuronal dysfunction (Cumiskey et al., 2005). LPS-induced
microglial activation is associated with subsequent astrocyte and
oligondendrocyte impairment and demyelination. LPS induction
of microglia caused a decrease in expression in several astro-
cytic proteins that are important for their normal function (e.g.,
Aqp4, a water transport channel). Astrocytes connect to each
other and to oligodendrocytes via gap junctions, and activated
astrocytes show reduced expression of connexins (30 and 43)
that mediate these junctions. As ions, water and osmolites are
exchanged via these connexins, loss of this connection leads to
decreased oligodendrocyte function and subsequent demyelina-
tion and neuronal impairment (Sharma et al., 2010). In astrocytes,
Dicer ablation causes changes in the transcriptome resulting in the
upregulation of many immature/reactive astrocyte genes, while
astrocytic genes related to mature astrocyte functions are down-
regulated (e.g., GLT-1). The alterations in astrocyte phenotype
occur already before neuronal deﬁcits were perceived, underlin-
ing the importance of proper astrocyte function in the brain (Tao
et al., 2011).
A DIVERGENCE IN UPS BETWEEN NEURONS AND GLIA
Since glia are essential for proper neuronal function, disturbances
in glial function can lead to excitotoxicity and neurodegeneration.
However, in neurodegenerative diseases with protein inclusions
(proteinopathies), neurons appear to be most vulnerable, as
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protein aggregation and cell degeneration is mainly observed in
neurons. Possibly these differences are due to dissimilarities in
their protein homeostasis. Indeed, distinct cell types show diver-
gent protein synthesis and degradation (Vilchez et al., 2012). In
addition, differences may exist in UPS levels and activity between
neurons and the various glial cells. The UPS is the main pro-
tein complex involved in the degradation of oxidized proteins,
and oxidation of nucleic acids, lipids and proteins is associated
with aging and neurodegenerative diseases (Mariani et al., 2005).
Proteasome inhibition causes an increase in nucleic acid oxi-
dation in both primary neurons and astrocytes; however, this
increase is much larger in neurons. This suggests that neu-
rons are more sensitive to proteasome inhibition, or are more
prone to oxidative stress, which is associated with neurodegen-
erative diseases like AD and Parkinson’s disease (PD; Ding et al.,
2004). The UPS appears to be less active in neurons in compar-
ison to white matter glia (Tydlacka et al., 2008). Intriguingly, in
response to cytokines such as TNF-α, IL-2, G-CSF, and IFNγ,
neurons upregulate the Ub-like protein ubiquitin D (or Fat10;
Lisak et al., 2011), which is able to target long-lived proteins
to the proteasome. Conversely, both astrocytes and microglia
failed to upregulate Fat10 upon cytokine stimulation (Hipp et al.,
2005), also indicating that the UPS is regulated in neurons in
another way. In contrast to most other neurodegenerative dis-
eases, in intranuclear inclusion body disease (INIBD) the largest
proportion of aggregates are found in glial cells (about 5% in
glial cells, compared to 1% in neurons). Here, most aggregates
are present in astrocytes, and a smaller proportion in oligo-
dendrocytes. All aggregates are positive for Ub, however, glial
cells seem to have a signiﬁcantly smaller proportion of aggre-
gates positive for the Ub-like proteins NEDD8, NUB1, and
SUMO1 than neurons. This slightly dissimilar composition of
the aggregates can be explained by either variations in protein
expression or protein recruitment toward the aggregates in the
cell types (Mori et al., 2012). In conclusion, neurons and glia
are differently reacting to proteasome inhibition and cytokines.
Besides, presence of UPS components in inclusion bodies seem
to diverge between neurons and glia, which could be indica-
tions why neurons are more vulnerable in neurodegenerative
diseases.
UPS IN GLIA IN RELATION TO NEURODEGENERATIVE
DISEASES
The tight balance between protein synthesis and degradation
is essential for cellular function. In the brain, disturbances
in either of the two cause the accumulation and aggregation
of short-lived and misfolded proteins. In aging neurons, UPS
activity has been shown to be decreased (Tydlacka et al., 2008),
accordingly, age-related alterations in proteasomal activity are
implicated in various neurodegenerative diseases (Tydlacka et al.,
2008; Tashiro et al., 2012; Lin et al., 2013; Orre et al., 2013).
It remains to be examined in more detail whether and how
proteasome levels and activity differ between neurons and glia,
which would obviously affect the capacity of cells to maintain
proper protein homeostasis. In many diseases protein aggre-
gates are hallmarks that are clearly visible in neurons, and are
indicative for neuronal dysfunction. However, aggregates are also
described in glial cells, for example in HD (Shin et al., 2005; Tong
et al., 2014) and amyotrophic lateral sclerosis (ALS; Bruijn et al.,
1997), although they are usually smaller or less abundant. The
discrepancy between the occurrence of neuronal and glial inclu-
sions implies that the UPS system is more efﬁcient to remove
aggregation-prone proteins in glia. Yet, while glia might be bet-
ter able to handle these proteins, this does not mean that glia
are not affected. Mainly astrocytes and microglia react to the
increase of aggregated proteins in the brain and show altered
function, thereby contributing to neuronal dysfunction. Many
studies have shown that neuronal UPS dysfunction plays an
important role in several neurodegenerative diseases. The ﬁrst
indications were found already more than 25 years ago, when
components of the UPS were found in inclusions of several neu-
rological diseases including PD,Pick’s disease but also in Rosenthal
ﬁbers in astrocytomas (Lowe et al., 1988). Depletion of 26S pro-
teasome in mice neurons led to signiﬁcant neurodegeneration
and inclusion body formation (Bedford et al., 2008). Although
the depletion was restricted to neurons, changes in glia were
observed as astrocytes showed an increase in GFAP and vimentin
protein expression, indicative of reactive gliosis (Elkharaz et al.,
2013). Interestingly, astrocytes themselves seem to be less sen-
sitive for proteasome inhibition. It has recently been suggested
that this is due to the high expression of the heat shock protein
HSP25 (Goldbaum et al., 2009). Although inhibition of protea-
somes by the reversible proteasome inhibitor MG-132 caused
aggresome formation and cytoskeletal disturbances in cultured
primary astrocytes, cell viability was only diminished by 20%.
Besides, cytoskeletal disturbances appeared to be reversible in
astrocytes, whereas in oligodendrocytes proteasome inhibition
massively induced apoptosis. This effect might be caused by the
induction of the HSP25, which is expressed at a much higher level
in astrocytes and interacts with all three types of cytoskeletal ﬁl-
aments in astrocytes. As downregulation of this protein indeed
resulted in fragmentation of actin networks, these results suggest
a protective role of HSP25 in the astrocyte cytoskeleton dur-
ing proteasome inhibition (Goldbaum et al., 2009). Proteasome
inhibition does not only change cell viability, it has also been
shown to decrease intermediate ﬁlament transcription in astro-
cyte cell lines. Treatment with proteasome inhibitors epoxomicin
and MG-132 decreased the mRNA levels of the astrocyte-speciﬁc
intermediate ﬁlament GFAP in different astrocyte cell lines. Simi-
larly, vimentin and nestin expression were signiﬁcantly decreased
upon proteasome inhibition in astrocytes, but not in neuronal
cells. Moreover, rat brains treated with proteasome inhibitors
through a cannula showed less astrogliosis around the cannula.
It appeared that the proteasome can affect GFAP promotor
activity by the degradation of its transcription factors, thereby
linking UPS activity directly to astrogliosis (Middeldorp et al.,
2009).
Cultured primary oligodendrocytes seem to be much more
sensitive to proteasome inhibition when compared to astro-
cytes. Treatment of these cells with MG-132 caused oxidative
stress, mitochondrial dysfunction and apoptosis after 18 h
(Goldbaum et al., 2006). While inhibition of the 26S reg-
ulatory subunit 7 (RPT1, part of 19S) speciﬁcally reduced
pro-inﬂammatory cytokine secretion in LPS-stimulated cultured
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microglia (Bi et al., 2012), in general also microglia showed
a decreased survival and an increase in pro-inﬂammatory
response following proteasome inhibition, including upreg-
ulation of nitric oxide and TNF-α secretion (Kwon et al.,
2008). LPS induction also triggers the secretion of these
cytokines bymicroglia, while intracellularly the pro-inﬂammatory
NF-κB pathway is upregulated. This process is controlled
by UPS components, with E3 ligase RING ﬁnger pro-
tein 11 (RNF11) as one of the key negative regulators
of the NF-κB pathway in microglia (Dalal et al., 2012).
In neurons and microglia, IFNγ caused induction of the
immunoproteasome by replacing the constitutive subunits
β1, β2, and β5 with the inducible immuno subunits β1i,
β2i, and β5i and the association with the regulatory com-
plex PA28αβ. Synergistically, LPS-induced neuroinﬂammation
can aggravate neurodegeneration that is triggered by pro-
teasome inhibition (Stohwasser et al., 2000; Pintado et al.,
2012).
Since both proteasome inhibition and neuroinﬂammation are
associated with neurodegenerative diseases, studying the interplay
between those two will provide new insights in neurodegener-
ative disease mechanisms. In the following section, proteasome
dysfunction and its effect on glia in several age-related neurode-
generative diseases are described and in Table 1 an overview of
the literature on a wider range of neurodegenerative diseases is
given.
ALZHEIMER’S DISEASE
Alzheimer’s disease is the most prevalent form of dementia and
is characterized by irreversible memory loss and impaired cog-
nitive functions. Magnetic resonance imaging (MRI) scans of
AD patient brains reveal atrophy and an enlargement of the
ventricles caused by neuronal shrinkage or cell loss, and loss
of (synaptic) connections is thought to be the main contrib-
utor to the cognitive and memory impairments (Bozzali et al.,
2011). Neuropathological hallmarks of AD are senile plaques
and neuroﬁbrillary tangles. Neuroﬁbrillary tangles are formed
by the hyperphosphorylated microtubule-associated protein tau
and are located mainly inside neurons, while extracellular the
senile plaques consist of aggregates formed by the peptide amyloid
β (Aβ). Over the last two decades, the concept of a neu-
roinﬂammatory involvement in AD has been established. This
started in 1986 with the discovery of plaque-associated reactive
microglia, and additional studies described the association of
both activated microglia and astrocytes with Aβ plaques express-
ing pro-inﬂammatory markers (Rozemuller et al., 1986; Grifﬁn
et al., 1989; Mrak, 2009). Astrocytes change their phenotype
when contacting extracellular Aβ, and their response includes
upregulation of glial ﬁbrillary acidic protein (GFAP), vimentin
and S100β (Grifﬁn et al., 1989; Kamphuis et al., 2012). In AD,
both astrocytes and microglia play an important role in clear-
ance of Aβ plaques (Wyss-Coray et al., 2003; Mandrekar et al.,
2009; Mulder et al., 2014). Besides, attenuation of astrocyte
Table 1 | Overview of published data on the role of glia and the UPS in several neurodegenerative diseases.
Disease Aggregation in glia UPS changes
Alzheimer’s disease and other tauopathies Tau in astrocytes and oligodendrocytes
(Ferrer et al., 2014)
Immunoproteasome induction in astrocytes and
microglia (Mishto et al., 2006; Nijholt et al., 2011;
Orre et al., 2013)
Huntington’s disease Htt in astrocytes (Shin et al., 2005; Tydlacka
et al., 2008; Tong et al., 2014)
Immunoproteasome induction in neurons
(Díaz-Hernández et al., 2003)
Parkinson’s disease and other α-synucleopathies α-syn in oligodendrocytes and possibly
astrocytes (Casarejos et al., 2009;
Stefanova et al., 2012; Pasanen et al., 2014)
No changes
Amyotrophic lateral sclerosis SOD1 and C9orf72 in astrocytes, microglia
and oligodendrocytes (Bruijn et al., 1997;
Forsberg et al., 2011; Mizielinska et al.,
2013)
TDP-43 in oligodendrocytes (Brettschneider
et al., 2013)
Immunoproteasome induction in astrocytes,
microglia, oligodendrocytes and neurons.
(Puttaparthi et al., 2007; Cheroni et al., 2009;
Bendotti et al., 2012)
TDP-43 aggregates are Ub positive (Zhang et al.,
2008)
Multiple sclerosis No aggregates Immunoproteasome induction in astrocytes,
microglia, neurons and lymphocytes (Mishto et al.,
2010; Zheng et al., 2012; Popescu et al., 2013;
Bellavista et al., 2014)
Alexander’s disease GFAP andTDP-43 in astrocytes in
Rosenthal ﬁbers (Brenner et al., 2001; Cho
and Messing, 2009; Sosunov et al., 2013;
Walker et al., 2014)
Impaired proteasome function in astrocytes (Tang
et al., 2006, 2010)
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activation leads to a higher plaque load and increased microglial
activation, probably as a compensatory mechanism (Kraft et al.,
2013). A loss in metabolic function of activated astrocytes wors-
ens the disease, and upregulation of GFAP has been shown
to correlate with downregulation of the astrocyte-speciﬁc glu-
tamate transporter EAAT2 (Simpson et al., 2010; Yan et al.,
2013).
Changes in the UPS pathway have been associated with AD
in several studies. Ub is accumulating in both plaques and
tangles (Chu et al., 2000). Next to the regular Ub protein in
the brains of AD and Down syndrome patients, both having
the plaque pathology, a unique form of ubiquitin B can be
found. This protein originates from a frameshift mutation in
the mRNA and leads to a protein with an aberrant C-terminus,
called UBB+1. It can be detected in all AD and Down syn-
drome patients, but in none of the non-demented controls (van
Leeuwen et al., 1998). Because of the absence of the carboxy-
terminal Gly-76, UBB+1 cannot ubiquitinate other proteins,
but is itself efﬁciently ubiquitinated. However, the proteasome
seems unable to degrade large amounts UBB+1, leading to pro-
teasome inhibition (Lam et al., 2000; van Tijn et al., 2007). In
addition, UBB+1 expression also changes the immune response
in astrocytes upon TNF-α and IFNγ treatment as secretion of the
chemokines CCL2 and CXCL8 is increased dramatically. This is
probably due to an upregulation of several proteins in the NF-κB
and JNKpathways, suggesting that a disruption in theUPS directly
inﬂuences pro-inﬂammatory signaling in astrocytes and vice versa
(Choi et al., 2013).
Importantly, alterations in the UPS can inﬂuence the degra-
dation of Aβ in both neurons and astrocytes. Although mainly
the neuronal viability is affected in response to increasing Aβ
levels, also astrocytes showed a similar upregulation in UPS
related proteins and a decrease in proteasome activities upon
Aβ treatment as neurons (Lopez Salon et al., 2003). Treatment
with Aβ oligomers decreased proteasome activity in vitro and
in mouse brain lysates, and a lower proteasome activity was
also observed in lysates of several brain areas of AD patients
(Gregori et al., 1995; Keller et al., 2000; Tseng et al., 2008; Zhao
and Yang, 2010). However, these measurements were mainly per-
formed in whole brain homogenates or in (neuronal) cell lines,
and may therefore fail to see alterations in immunoproteasome
levels and activity in glial cells since that was not investigated
in these studies. More recently, it was shown that Aβ treatment
led to an increase in proteasome activity in both cultured neu-
rons, astrocytes and microglia. In addition, it was discovered
that both mRNA and protein levels of immunoproteasome sub-
units β5i and β1i were upregulated in reactive astrocytes and
microglia around plaques in AD mice and human AD patient
material, whereas in AD mice the levels of β2i were similar to con-
trols. Consistently, the activity of all immunoproteasome subunits
was increased with increasing plaque load in both AD mice and
in post-mortem material of human AD patients (Nijholt et al.,
2011; Orre et al., 2013). These results are in line with earlier
data showing that β1i expression levels in neurons and astro-
cytes were increased with age, and in the brain areas most affected
in AD (Mishto et al., 2006). While it becomes clear that espe-
cially immunoproteasome activity is increased in glia during AD,
it remains to be examined whether these changes are beneﬁcial
or not.
PARKINSON’S DISEASE
Parkinson’s disease is after AD the most common neurodegener-
ative disease with an incidence of 0.3% in the total population.
The incidence increases with age leading to 4% of people above
the age of 80 suffering from this mostly idiopathic movement dis-
order (Imai et al., 2000; de Lau and Breteler, 2006). The etiology
of the disease is not known, although there are some familial cases
caused by mutations in the genes of, e.g., alpha-synuclein (α-syn)
and E3 ligase parkin. Also mutations in UCH-L1, a Ub c-terminal
hydrolase, have been associated with PD but this ﬁnding is con-
troversial (Hardy et al., 2009). In PD, the dopaminergic neurons
in the substantia nigra pars compacta degenerate, which is accom-
panied with eosinophillic intracytoplasmatic inclusions known
as Lewy bodies (LBs) and gliosis. While microgliosis is domi-
nantly present in PD, reactive astrogliosis is virtually absent (Mirza
et al., 1999; Van Den Berge et al., 2010; Halliday and Stevens,
2011). Although they do not change their phenotype, astrocytes
are affected by α-syn accumulation. Astrocytes are able to take
up α-syn released from neurons, and subsequently secrete pro-
inﬂammatory cytokines (TNF-α and CXCL1), thereby activating
microglia (Lee et al., 2010). These results were conﬁrmed in a study
using a mouse model expressing α-syn in astrocytes only, which
caused similar disease symptoms, astrocyte functional loss and
activated microglia. As the pro-inﬂammatory response of these
cells caused neurodegeneration (Gu et al., 2010), this suggests that
glial dysfunction plays a signiﬁcant role in the etiology of PD.
A role for the UPS in PD was ﬁrst described in familial PD
when it was discovered that mutations in the protein parkin were
associatedwith familial PD. Parkin functions as aUb ligase in asso-
ciation with proteasomal degradation (Imai et al., 2000). A subset
of the mutations in parkin, but also post-translational modiﬁca-
tions of the protein, have been shown to cause a loss of function
of the E3 ligase, and have been associated with UPS impairment
and abrogation of the neuroprotective effects of parkin (Tsai et al.,
2003; Yamamoto et al., 2005; Ali et al., 2011). In addition, Lewy
bodies are mainly composed of α-syn and cytoskeletal proteins,
but next to these proteins Lewy bodies contain the UPS related
proteins parkin and Ub (Shults, 2006). Induced mutant α-syn
expression was reported to decrease proteasome activity in cul-
tured cells and a decreased proteasome activity was detected in the
substantia nigra of PD patients (Tanaka et al., 2001; McNaught
et al., 2003). These ﬁndings are in contrast with a study that
showed that overall proteasome activity was not decreased in brain
regions with Lewy body pathology (Tofaris et al., 2003). The dis-
crepancy between these results can be explained by the technique
that was used to measure proteasome activity in these studies.
The AMC-peptides are rather non-speciﬁc since also other pro-
teases can cleave these peptides, thereby inﬂuencing the results.
Therefore, the exact role of UPS in PD is still under debate. Cul-
tured parkin knock-out neurons appeared to be more resistant
to mild proteasome inhibition than wild type neurons due to
upregulation of anti-oxidant scavenger protein glutathione and
autophagy-related proteins. In contrast, parkin knock-out glia
(mixed population, mainly astrocytes) were more susceptible to
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epoxomicin-induced cell death than wild type glia, suggesting that
parkin dysfunction in PD mainly affects glia. In contrast to neu-
rons, this effect on parkin knock-out glia was associatedwith lower
levels of glutathione, a decreased HSP70 response, and an increase
in poly-ubiquitinated proteins, all contributing to glial dysfunc-
tion. Besides, conditioned medium of parkin knock-out glia was
less neuroprotective. So proteasome inhibition causes glial dys-
function and is therefore possibly the reason for the pathology
in Parkin knock-out mice (Solano et al., 2008; Casarejos et al.,
2009). Correspondingly, proteasome inhibitors had deleterious
effects in mice expressing α-syn only in oligodendrocytes. The
mice showed motor symptoms and severe degeneration in the
nigrostriatal pathway caused by myelin disruption and demyeli-
nation in oligodendrocytes that had accumulated α-syn ﬁbrils in
their cytoplasm (Stefanova et al., 2012). Overall in PD, inhibition
of theUPS system seems to contribute to glial dysfunction, thereby
also affecting neuronal function. However, similar to AD the exact
mechanism causing proteasome changes and neurodegeneration
still needs to be unraveled.
HUNTINGTON’S DISEASE
HD is a severe familial neurodegenerative disease typiﬁed by
chorea (abnormal involuntary limb movements), incoordination,
cognitive decline, and behavioral difﬁculties (Walker, 2007). The
prevalence of this autosomal dominant heritable disease is ﬁve
to seven affected individuals per 100,000 people in the West-
ern world. HD is characterized by neuronal and glial aggregates,
neuronal dysfunction and neurodegeneration, starting in the
striatum and the cerebral cortex (corticostriatal pathway). An
individual is affected when the polyglutamine (polyQ) repeat
present in the disease-related huntingtin (HTT) protein exceed
36–41 glutamines (Walker, 2007). The encoding CAG repeats
are not unique for HD as at least eight other neurodegenerative
disorders are caused by a similar polyQ expansion in differ-
ent proteins. Although the cause is already known for decades,
the exact disease mechanism is still unclear. Interestingly, even
though every cell in the body expresses the polyQ-expanded pro-
teins, mainly neurons are affected and degenerate (Han et al.,
2010). Fragments of the polyQ-expanded HTT are thought
to initiate aggregation, and the resulting protein aggregates or
inclusion bodies (IB) are an important hallmark of HD. More
recently it became clear that these IBs are not necessarily causing
neurodegeneration, as the formation of IBs did not corre-
late with cell death in cultured striatal neurons (Saudou et al.,
1998). The formation of IBs may even be a protection mech-
anism of the cell to sequester toxic monomers and oligomers,
thereby promoting cell survival (Arrasate et al., 2004; Truant et al.,
2008).
Intriguingly, glial cells hardly show aggregates in HD patient
material, while the expanded HTT is also expressed in these
cells (Shin et al., 2005). Still, neuropathological studies show
glial involvement in HD by phagocytosis of dead neurons and
activated astrocytes (Reddy et al., 1998; Li et al., 2003), and the
severity of both astrogliosis and microgliosis correlates with dis-
ease progression (Sapp et al., 2001; Faideau et al., 2010). Increased
GFAP expression and activated microglia are already observed in
presymptomatic stages inHDpatients.With increased aggregation
in neurons also the number of activated microglia and astrocytes
increases (Sapp et al., 2001; Faideau et al., 2010). In addition, both
microglial cell lines expressing polyQ-expandedHTT and primary
microglia from early postnatal HD mice were strongly impaired in
theirmigration toward chemotactic stimuli, and showeda retarded
response to laser-induced brain injury in vivo (Kwan et al., 2012).
This suggests that polyQ-expanded HTT expression inﬂuences the
appearance and function of reactive microglia. Similarly, astro-
cytes showed a loss of their regulatory functions: in the R6/2 HD
mouse model decreased levels of glutamate transporters and glu-
tamate uptake were observed, eventually leading to excitotoxicity
(Shin et al., 2005). Intriguingly, excitotoxicity also occurred when
polyQ-expanded HTT is only expressed in striatal astrocytes but
not in neurons (Faideau et al., 2010;Wang et al., 2012). In addition,
astrocytes isolated from R6/2 mice suppressed the secretion of the
chemokine CCL5/RANTES and of BDNF, which is a growth fac-
tor important for neuronal survival, thereby inhibiting the trophic
functions of astrocytes (Chou et al., 2008). So despite the low
abundance of IBs, exclusive expression of polyQ-expanded HTT
in astrocytes caused a decrease in glutamate uptake followed by
excitotoxicity, neurodegeneration and an age-dependent HD-like
phenotype in mice (Bradford et al., 2009), suggesting a crucial role
for astrocytes in HD that is directly affected by polyQ-expanded
HTT.As astrocytes and microglia hardly show IB formation in HD
and when they appear, they are much smaller in size (Shin et al.,
2005), differences in HTT ubiquitination or proteasome activity
might explain these dissimilarities.
An important role for the UPS in HD was suggested in
the late nineties, when Ub and proteasomes were found to be
colocalized with HTT aggregates as shown by immunohisto-
chemistry in HD mice and post-mortem patient material (Davies
et al., 1997; DiFiglia et al., 1997). This led to the hypothe-
sis that components of the UPS were irreversibly sequestered
into HTT aggregates, as was also suggested by FRAP studies
that showed no ﬂuorescence recovery after photobleaching in
ﬂuorescently tagged proteasomes that were present in aggre-
gates (Holmberg et al., 2004). However, we recently showed
with ﬂuorescent pulse-chase experiments that proteasomes were
exchanged in HTT aggregates but with slower kinetics than it
would be detectable by FRAP analysis (Schipper-Krom et al.,
2014). This indicates that proteasomes are dynamically recruited
into HTT aggregates. Since soluble HTT can be ubiquitinated,
HTT can be targeted for proteasomal degradation (Thomp-
son et al., 2009; Juenemann et al., 2013). However, various
studies have reported an impairment of the proteasome sys-
tem in both HD cell models and in the brain of HD patients
(Seo et al., 2004; Hunter et al., 2007). Moreover, impairment
of the proteasome causes accumulation of the potentially toxic
aggregation-prone N-terminal HTT fragments (Li et al., 2010).
Yet, proteasomes are able to degrade polyQ-expanded HTT frag-
ments efﬁciently and entirely, but only when HTT is efﬁciently
targeted for degradation by ubiquitination (Juenemann et al.,
2013). Together these results suggest a crucial role for the UPS
in HD pathogenesis.
Cellular stress due to polyQ-expanded HTT in neurons can
lead to proteasome subunit changes, as increased levels of the
IFNγ-inducible immunoproteasome subunits LMP2 and LMP7
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were observed in cortex and striatum of both HD mice and
post-mortem HD patient material. Interestingly, this increase was
mainly attributed to degenerating neurons (Díaz-Hernández et al.,
2003), and may be the result of glial cytokine secretion. It is
unknown whether glial cells upregulate immunoproteasomes in
HD, and whether the induction of the immunoproteasome is ben-
eﬁcial in HD. While these proteasomes are better capable to deal
with protein aggregates under oxidative stress (Seifert et al., 2010),
it is unknown whether immunoproteasomes are also better capa-
ble to degrade polyQ-expandedHTT fragments. Still, the apparent
absence of HTT aggregates in glial cells remains intriguing, and
may be explained by observed differences in proteasome activity
in wild type mouse brains where glial cells showed increased pro-
teasome activity when compared to neurons. It remains, however,
to be examined whether this explains the differences in aggregate
size and abundance. Remarkably, when polyQ-expandedHTTwas
present in R6/2 mice, proteasome activity levels were not altered
(Tydlacka et al., 2008), although this does not reﬂect any possible
changes in proteasome composition. The latter ﬁnding is under-
scored by a recent study, where it was shown by using proteasome
activity-based probes that proteasomes recruited into aggregates
were accessible for substrates and remained active. Besides, no
differences were observed in overlay proteasome activity between
HD and wild type mice (Schipper-Krom et al., 2014). Together,
this indicates that the overall activity of the proteasome does not
change in HD, although the composition of proteolytic subunits
undergoes some alterations. Therefore, studying the role of the
UPS in glial cells in HD is of high importance.
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis is a late onset, rapidly progres-
sive and ultimately fatal neurological disorder, characterized by
muscle weakness and atrophy leading to the inability to con-
trol voluntary movements. These symptoms are caused by the
loss of motor neurons in the brain and spinal cord. Prevalence
is increasing with age from overall 4–6 cases per 100,000 to
up to 33 cases per 100,000 in 60–75-year-olds. About 10% of
these patients have the familial form of ALS, often caused by
mutations in the gene coding for copper-zinc superoxide dis-
mutase (SOD1; Majoor-Krakauer et al., 2003). Motor neuron
degeneration is often preceded by the formation of nuclear inclu-
sions containing ALS associated proteins SOD1, TDP-43. or
FUS and are usually also Ub positive (Leigh et al., 1991; Ben-
dotti et al., 2012). Glial pathology is strongly present in ALS as
observed in cell models, mice and post-mortem patient mate-
rial (Alexianu et al., 2001; Petrik et al., 2007; Evans et al., 2013).
Although SOD1 expression in microglia or astrocytes alone is
not sufﬁcient to cause ALS phenotype in mice, transplantation
of healthy microglia in SOD1 mutated mice slows down disease
progression (Gong et al., 2000; Clement et al., 2003; Beers et al.,
2006). In addition, SOD1 expression alone in motor neurons
does not cause ALS pathology, suggesting that glial function is
important in ALS development (Pramatarova et al., 2001). Nor-
mally, astrocytes are secreting numerous trophic factors, like
VEGF and BNDF to promote neuronal survival, and they take
up glutamate from the synaptic cleft. However, activated astro-
cytes in ALS showed disturbances in these functions, eventually
leading to excitotoxicity (Trotti et al., 1999; Evans et al., 2013).
Recently, it was shown that a mutation in C9orf72 could lead to
aggregates in neurons, astrocytes, microglia and oligodendrocytes
(Mizielinska et al., 2013). Besides, affected astrocytes caused neu-
ronal cell death when co-cultured, suggesting an important role
of astrocytes in this disease (Meyer et al., 2014). Microglia have
been shown to secrete IL-1β as a response to puriﬁed mutant
SOD1 stimulation, which is thus an important pro-inﬂammatory
trigger (Meissner et al., 2010). Also secretion of several other
pro-inﬂammatory cytokines such as TFN-α, IFNγ, and IL-6 was
reported, resulting in (more) activationof astrocytes andmicroglia
(Evans et al., 2013).
Similar to the neurodegenerative diseases described above also
impairment of several components of the UPS is observed in
ALS, which is likely a cause or consequence of the protein aggre-
gates that are widely present (Kabashi et al., 2008; Bendotti et al.,
2012). Impairment of the UPS but not of the autophagic path-
way led to ALS-like symptoms in mice. Conditional knock-out of
the 19S proteasome subunit RPT3 speciﬁcally in motor neurons
caused accumulation of ALS related proteins (FUS and TDP-43)
in these cells, and led to reactive gliosis and motor dysfunction.
A knock-out of autophagy associated gene Atg5 only led to accu-
mulations of Ub and p62 in the cytoplasm but not of ALS-related
proteins (Tashiro et al., 2012). While impairment of the UPS in
motor neurons induced an ALS-like phenotype, immunohisto-
chemical studies showed signiﬁcantly increased levels of Ub and
proteasome subunits in both motor neurons and astrocytes inALS
(Aquilano et al., 2003; Mendonça et al., 2006). This contradictory
result could be explained by ﬁndings in an ALS mouse model
where a decrease in constitutive proteasome and an increase in
immunoproteasome levels were observed, which correlated with
the glia-mediated inﬂammatory response. Also the levels of the
reactive astrocyte marker GFAP, the microglia marker CD68, and
secretion of the cytokine TNF-αwere upregulated in the ALS mice
in a presymptomatic stage (Cheroni et al., 2009). Motor neurons
in ALS also showed an upregulation of PA28αβ which could lead
to a decrease in the turnover of ubiquitinated proteins as this
requires the 19S activator (Bendotti et al., 2012). However, when
mutant SOD1 mice were crossed with β1i/LMP2 knockout mice,
the absence of immunoproteasomes in vivo could not signiﬁcantly
prevent mutant SOD1-induced disease; as no changes in disease
symptoms were observed (Puttaparthi et al., 2007). So while acti-
vated astrocytes and microglia secrete cytokines that result in the
induction of immunoproteasomes in both glia and neurons, these
changes seem to be not beneﬁcial in the clearance of accumulating
SOD1 proteins.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Studies on the role of the UPS in neurodegenerative disease are
mainly focusing on neurons, as these diseases are often consid-
ered to be cell autonomous due to the fact that neurons appear
to be the most severe affected. Recently, however, the role of glial
cells in neurodegenerative diseases is emerging. The fact that glial
activation can already be observed in early presymptomatic stages
advocates for an important if not crucial role for glial cells in the
initiation of these diseases (Tai et al., 2007; Faideau et al., 2010).
Glial cells express most of the disease-related proteins, and glial
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aggregates are observed in some of these neurodegenerative dis-
eases albeit with lower frequencies (Bruijn et al., 1997; Shin et al.,
2005; Tong et al., 2014). In addition, the disease-causing proteins
can alter glial function by the induction of secretion of various
cytokines. This makes glial cells important players in the various
diseases, as the interplay between disease-causing proteins and the
altered UPS not only affects glial cell homeostasis, but indirectly
also neuronal function. A common hallmark of the here discussed
various neurodegenerative diseases is the general downregulation
of the constitutive proteasome accompanied by an upregulated
immunoproteasome. This is in line with the observed pheno-
typical alterations that microglia and astrocytes undergo during
disease progression, and the resulting pro-inﬂammatory environ-
ment correlates perfectly with the induction of the immunopro-
teasome. The induced immunoproteasomes may be better able to
degrade intracellular protein aggregates, as suggested for protein
aggregates that are induced following IFNγ-induced stress (Seifert
et al., 2010). Since IFNγ is secreted by microglia (Kawanokuchi
et al., 2006) and is able to activate both microglia and astrocytes in
several neurodegenerative diseases (Choi et al., 2013; Evans et al.,
2013), most likely the observed immunoproteasome induction is
mediated by microglia. Nevertheless, while immunoproteasomes
are directly induced by IFNγ, this cytokine also induces the accu-
mulation of oxidized proteins that may accelerate aggregation and
affect protein homeostasis in time. Still, the induced immuno-
proteasomes appear better capable to degrade polyubiquitinated
proteins under these circumstances, and proteolytic activity of
immunoproteasomes is higher compared to standard proteasomes
(Seifert et al., 2010). These data suggest that activation of glia
and induction of the immunoproteasome may be beneﬁcial for
clearing disease-causing proteins.
Yet, similar to chronic activation of glia, it is unknown whether
induction of the immunoproteasome is on the long term bene-
ﬁcial or detrimental in neurodegenerative diseases. After all, the
increased immunoproteasome induction in these diseases and in
aging could also indicate undesirable protein accumulation and
chronic inﬂammation (Díaz-Hernández et al., 2003; Mishto et al.,
2006; Cheroni et al., 2009; Nijholt et al., 2011; Orre et al., 2013;
Bellavista et al., 2014). When the induction of the immunopro-
teasome is not beneﬁcial in targeting the accumulating proteins,
speciﬁc inhibitors targeting immunoproteasome subunits could
be an efﬁcient therapeutic approach. Although several of these
inhibitors are already developed (Miller et al., 2013), more insight
is required in the exact function of the immunoproteasome in
these disorders.
Next to focusing on proteasome activity, for future approaches
it is also important to examine which other alterations in the
UPS observed in glia can be used as possible therapeutic targets.
Although proteasome compositional changes appear in glial cells
during disease progression, in general proteasomes stay active and
accessible even in cells showing large protein aggregates (Tydlacka
et al., 2008; Basler et al., 2013; Orre et al., 2013; Schipper-Krom
et al., 2014). Yet, it is unclear whether the diseased proteins are
correctly targeted for degradation, as inefﬁcient ubiquitination of
mutant and misfolded proteins could explain the observed protein
accumulations and neuronal vulnerability. Improved targeting of
the disease-causing proteins toward the proteasome by modifying
ubiquitination (or with other Ub-like proteins) would increase
their degradation and delay onset of disease. It is unknown
whether the ubiquitination patterns of the various disease-related
proteins in glia and neurons is dissimilar and whether they change
during disease progression. Therefore, determining the ubiquiti-
nation patterns of these proteins in different stages of disease in
both neurons and glia, along with determining the involved spe-
ciﬁc ubiquitin ligases and DUBs in these cells should lead to the
identiﬁcation of new and more speciﬁc therapeutic targets.
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